Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
NCT06203600 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- June 24, 2024
- Completion date
- October 31, 2027
- Enrollment
- 224 (estimated)
- Sites
- 375
Conditions
As the registry lists them; a condition with its own page is linked.
advanced esophageal adenocarcinoma, advanced gastric adenocarcinoma, advanced gastroesophageal junction adenocarcinoma, clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, metastatic esophageal adenocarcinoma, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, unresectable esophageal adenocarcinoma, unresectable gastric adenocarcinoma, unresectable gastroesophageal junction adenocarcinoma